ArticleFrontiers in oncology2025
First evidence of Retzius-sparing robot-assisted radical prostatectomy with the Versius robotic surgical system.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the first experience of Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) performed with the Versius robotic system (CMR Surgical, Cambridge, UK). Five patients underwent RS-RARP at ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy) between May 2023 and December 2023. All procedures were completed with no complications or need for conversion. No arms collision or technical failure of the system was recorded. The median operative time was 244 minutes (interquartile range [IQR]: 190-300). Median length of stay was three days. Our initial experience suggests that RS-RARP with the Versius robotic system is a feasible procedure. This novel platform provides a flexible system environment that can be easily tailored to all types of surgery. However, some arrangements are still necessary, warranting future investigations in larger series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.